Latest Blog Posts Tagged "Industry & Nonprofit Collaboration"
October 25, 2018
'Forbes' published a story detailing a 'milestone moment' in the history of LRRK2 and role of the Foundation in ushering this promising genetic target forward.
October 24, 2018
Cerevel Therapeutics gains preclinical and clinical-stage drugs from Pfizer's previous neuroscience program.
September 13, 2018
Deputy CEO, Sohini Chowdhury, talked to Roche for an article discussing PPMI and the importance of sharing data.
June 20, 2018
The Michael J. Fox Foundation gathered leaders from industry, academia, non-profits and government to discuss the way forward in Parkinson's drug trials.
March 20, 2018
The Lancet Neurology calls the AMP PD program the 'most ambitious initiative so far to find a cure for Parkinson's.'
July 21, 2015
Pfizer video highlights collaboration with The Michael J. Fox Foundation.
February 04, 2015
The Foundation has united three powerhouse pharmaceutical companies for a pre-competitive consortium to advance LRRK2 inhibitors as potential disease-modifying medications.
December 04, 2013
As part of this ongoing series, we ask a researcher three questions to learn what their days are like in and out of the lab.
November 22, 2013
In the latest issue of The Sherer Report, The Michael J. Fox Foundation's CEO says now is the time to mobilize around PD research.
July 03, 2013
Repositioning is the process of testing a drug that is already FDA-approved or that has been proven safe for a certain indication, to determine whether it might work in another disease, such as PD.